Patients treated with Odactra experienced a 22% reduction in total combined rhinitis score compared with placebo. The expanded approval was supported by data from a phase 3 trial (ClinicalTrials ...
The U.S. Food and Drug Administration has expanded its indication of Odactra, a house dust mite allergen tablet, for the ...
ALK (ALKB:DC / OMX: ALK B) today announced that the US Food and Drug Administration (FDA) has approved ALK’s ODACTRA ® tablet for use in young children with house dust mite (HDM) allergy.
a house dust mite allergen tablet, for the treatment of house dust mite-induced allergic rhinitis, with or without conjunctivitis, to include children ages 5 through 11 years. Odactra is an ...
The U.S. Food and Drug Administration has expanded its indication of ALK's Odactra, a house dust mite allergen tablet, for the treatment of house dust mite-induced allergic rhinitis, with or ...
WEDNESDAY, March 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has expanded its indication of Odactra, a house dust mite allergen tablet, for the treatment of house dust mite ...
From breaking news to special features, we're on it! Join the NonStop Local Chord group and always be in the know. WEDNESDAY, March 5, 2025 (HealthDay News) -- The U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results